Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.
Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 15, 7, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.
Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
– The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 5
Allergic Rhinitis – Overview 7
Allergic Rhinitis – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 19
Allergic Rhinitis – Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Allergic Rhinitis – Companies Involved in Therapeutics Development 28
Accolade Pharmaceuticals LLC 28
AFFiRiS AG 28
ALK-Abello A/S 29
AlleCures Inc 30
Allergy Therapeutics Plc 30
ASIT Biotech SA 31
Axikin Pharmaceuticals Inc 31
Chong Kun Dang Pharmaceutical Corp 32
Chrysalis BioTherapeutics Inc 32
Fountain Biopharma Inc 33
GlaxoSmithKline Plc 33
Glenmark Pharmaceuticals Ltd 34
HAL Allergy BV 34
Hisamitsu Pharmaceutical Co Inc 35
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: